Tina Firouzbakht
Cardiovascular Disease · Shreveport, LANPI 1891115846
Payments from drug & device makers
What this record shows
This record is dominated by grants: $23,054 of the $27,800 with a category attached, or 82.9%. Medtronic accounts for 92.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $12,513 and has fallen 97.2% since, to $355 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $205.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$457
- Abiomed$347
- E.r. Squibb & Sons, L.L.C.$251
- Pfizer$197
- Abbott$118
- plus $652 from 19 others
What the payments were for
- Grants$23,05483%
- Travel & lodging$1,6686%
- Food & beverage$2,94811%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 34 | $25,778 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $457 |
| Abiomed | 5 | $347 |
| E.r. Squibb & Sons, L.L.C. | 14 | $251 |
| Pfizer | 13 | $197 |
| Abbott | 1 | $118 |
| Bayer | 3 | $58 |
| Irhythm Technologies, Inc. | 2 | $56 |
| Boston Scientific | 3 | $56 |
| Baxter Healthcare | 3 | $51 |
| Kestra Medical Technology Services, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Amgen | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Novo Nordisk | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| Philips North America LLC | 2 | $29 |
| Johnson & Johnson | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Inari Medical, Inc. | 1 | $17 |
| Recor Medical Inc | 1 | $16 |
| Merck | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,800 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $106,653 |
| XareltoRivaroxaban | 30 | $29,069 |
| Amiodarone Hcl | 28 | $1,942 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $1,703 |
| Flecainide Acetate | 26 | $1,616 |
| Metoprolol Succinate | 94 | $797 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $751 |
| Amlodipine Besylate | 86 | $310 |
| Atorvastatin Calcium | 25 | $296 |
| Metoprolol Tartrate | 73 | $275 |
| Rosuvastatin Calcium | 15 | $196 |
| Losartan Potassium | 28 | $183 |
| Hydrochlorothiazide | 14 | $156 |
| Ezetimibe | 17 | $139 |
| Diltiazem Hcl | 11 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $197 | $106,653148 claims |
| Johnson & JohnsonXarelto | $19 | $29,06930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Wenwu ZhangShreveport$21K
- William EavesShreveport$15K
- Jagan BeedupalliShreveport$13K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.